axicabtagene ciloleucel

This page shows the latest axicabtagene ciloleucel news and features for those working in and with pharma, biotech and healthcare.

Gilead strikes $5.1bn deal to bolster ties with Galapagos

CAR-T therapy for cancer Yescarta (axicabtagene ciloleucel) – acquired as part of its $12bn takeover of Kite – has been slow to build sales, bringing in $264m last year.

Latest news

Regeneron's bispecific for lymphoma works in CAR-T failures

At the moment, Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) are the CAR-Ts that have been approved to treat DLBCL, with pivotal trials showing that they can
MorphoSys eyes 2020 launch for lymphoma CAR-T challenger

and Gilead’s Yescarta (axicabtagene ciloleucel).
Gilead unveils plan to separate Kite cell therapy unit

The announcement, which was announced internally in March, comes as the company’s first CAR-T therapy Yescarta (axicabtagene ciloleucel) for lymphoma continues to show somewhat sluggish growth, with first quarter
CMS proposes coverage scheme for CAR-T therapies

Sciences’ Yescarta (axicabtagene ciloleucel) given the nod shortly afterwards for various forms of non-Hodgkin’s lymphoma (NHL) including DLBCL.
CAR-Ts take centre stage as ASH18 comes to a close

Gilead also had new, two-year data to share on its already-marketed CAR-T Yescarta (axicabtagene ciloleucel) in r/r B-cell lymphoma that showed a sustained treatment effect, answering

More from news
Approximately 1 fully matching, plus 29 partially matching documents found.

Latest Intelligence

The European Medicines Agency: PRIME’d for access?

Early signs are looking good: Novartis’ Kymriah (tisagenlecleucel) and Gilead/Kite’s Yescarta (axicabtagene ciloleucel) secured positive opinions from EMA's Committee for Medicinal Products for Human Use (CHMP) in June
Deal Watch January 2017

Kite Pharma. Daiichi Sankyo. Licence. Cellular cancer therapy axicabtagene ciloleucel (KTE-C19).

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Senior Account Manager > Account Director - London - Medical ...: Salary TBC

FREELANCE Medical Writer (Initial 2/ 3 months term) - London Off...: Excellent Daily Rate

Strategic Planner, Healthcare Advertising Agency: Salary TBC

Senior Medical Writer, Healthcare Advertising Agency: £45, 000 – £50, 000

Account Director - Healthcare Advertising - London - 2 DAYS HOME...: £50000 - £70000

Account Director – London based Medical Communications Agency: Excellent Remuneration Package

FREELANCE Account Director – Healthcare Advertising – London – 3...: Competitive Daily Rates

Account Director - Medical Communications - London / South East: Excellent Salary and Benefits on offer

Account Director – UK Office: Excellent salary and benefits

Senior Account Executive – Account Manager – Healthcare Advertis...: £32000 - £43000 Bonus Benfits

Account Director, Healthcare Communications: Salary TBC

Subscribe to our email news alerts

PMHub

Add my company

Havas Lynx Group

We are the Havas Lynx Group. Devoted to fresh thinking. Changing the way the world does healthcare communications for the...

Latest intelligence

Blended Intelligence: Data is the most valued commodity of the modern world. For P&P it's all about the application....
The relevance of patient perspectives to value: Exploring the evolution of patient involvement in health technology assessment, and the role of the patient voice in market access....
How is the NHS Long-term Plan being put into action?: Steve How, Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore some of the changes that have occurred since the plan was published...